2:41
ASCOGU 25: Brad McGregor, MD, on TIVO in kidney cancer | Dana-Farber Cancer Institute
Dana-Farber Cancer Institute
2:26
ASCOGU 25: Brad McGregor, MD Immunotherapy in bladder cancer | Dana-Farber Cancer Institute
2:05
ASCOGU25: Alicia Morgans, MD, MPH, COGCaP | Dana-Farber Cancer Institute
2:49
ASCOGU25: Atish Choudhury, MD, PhD | Dana-Farber Cancer Institute
2:27
ASCOGU25: Toni Choueiri, MD, on LITESPARK003 | Dana-Farber Cancer Institute
1:54
ASCOGU25: Toni Choueiri MD., on Casdatifan | Dana-Farber Cancer Institute
1:26
ASCOGU25: Dr. Vincent Xu, MD, on KIM1 | Dana-Farber Cancer Institute
1:41
Kidney Cancer CLEAR Trial biomarker analysis: Toni Choueiri, MD | Dana-Farber Cancer Institute
1:28
Kidney Cancer JAVELIN 101: Toni Choueiri, MD | Dana-Farber Cancer Institute
2:23
ASCO #GU24: Alok Tewari, MD, PhD | Dana-Farber Cancer Institute
2:35
ASCOGU24: Toni Choueiri, MD | Dana-Farber Cancer Institute
2:22
ASCOGU24: Xiao Wei, MD on LuPSMA | Dana-Farber Cancer Institute
2:01
ASCOGU24: Xiao Wei, MD on TPS244 | Dana-Farber Cancer Institute
2:31
ASCOGU24: Alicia Morgans, MD | Dana-Farber Cancer Institute
1:20
ASCOGU24: Himisha Beltran, MD | Dana-Farber Cancer Institute
2:38
ASCOGU24: Avina Rami | Dana-Farber Cancer Institute
2:43
ASCO GU 23 Penile Cancer Research | Dana-Farber Cancer Institute
2:29
ASCO GU23 Treatment-free survival in kidney cancer | Dana-Farber Cancer Institute
1:08
ASCO GU23 CheckMate-9ER Biomarker Analysis: Toni Choueiri, MD | Dana-Farber Cancer Institute
1:19
ASCO GU23 Triplet therapy in kidney cancer: Toni Choueiri, MD | Dana-Farber Cancer Institute
1:22
ASCO GU23 Toni Choueiri, MD: CheckMate-9ER 3-year follow-up | Dana-Farber Cancer Institute
1:01
ASCO GU23 Toni Choueiri, MD: KEYNOTE-564 subgroup analysis | Dana-Farber Cancer Institute
2:42
ASCO GU23 Paul Nguyen, MD: FORMULA-509 | Dana-Farber Cancer Institute
1:30
Kidney Cancer Research: Immunotherapy after surgery | Dana-Farber Cancer Institute
1:57
Bladder Cancer Research: Multiplexed autoantibody profiling | Dana-Farber Cancer Institute
Prostate Cancer Research: Mapping the patient journey | Dana-Farber Cancer Institute
1:14
COVID-19 and Genitourinary Cancer: Pandemic's impact | Dana-Farber Cancer Institute
1:25
Bladder Cancer Research: Immunotherapy outcomes | Dana-Farber Cancer Institute
1:56
Rare Cancer: Immunotherapy in genitourinary cancer | Dana-Farber Cancer Institute
1:17
Bladder Cancer Research: Metabolomic plasma profiling | Dana-Farber Cancer Institute
Bladder Cancer Advances | ASCO GU21
2:03
Dana-Farber Cancer Institute: Mary-Ellen Taplin, MD (ASCO GU21 prostate cancer)
1:52
Dana-Farber Cancer Institute: Andrew L. Schmidt, MBBS at ASCO GU21 (kidney cancer)
2:02
Dana-Farber Cancer Institute: Guru Sonpavde, MD at ASCO GU21 (bladder cancer)
2:07
Dana-Farber Cancer Institute: Guru Sonpavde, MD (bladder cancer research at ASCO GU21)
Dana-Farber Cancer Institute: Wenxin Vincent Xu, MD at ASCO GU21 (kidney cancer)
1:42
Dana-Farber Cancer Institute: Toni K. Choueiri, MD (kidney cancer research at ASCO GU21)
1:49
Dana-Farber Cancer Institute: Guru Sonpavde, MD at ASCO GU21 (urothelial carcinoma)
2:08
Dana-Farber Cancer Institute: Toni K. Choueiri, MD at ASCO GU 21 (kidney cancer)
